Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
GLP-1R antagonist 1
Cat. No.:
OB0225LY-0264
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by HPLC.
Size:
Product Overview
Description:
GLP-1R antagonist 1 is a selected peptide analog that specifically inhibits glucagon-like peptide-1 (GLP-1) receptor activity and affects signaling pathways associated with glucose metabolism.
Synonym:
488097-06-9; 7-(4-Chlorophenyl)-1,3-dimethyl-5,5-bis(trifluoromethyl)-8H-pyrimido[4,5-d]pyrimidine-2,4-dione; 7-(4-Chlorophenyl)-5,8-dihydro-1,3-dimethyl-5,5-bis(trifluoromethyl)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione
CAS No.:
488097-06-9
Compound CID:
1941609
Formula:
C16H11ClF6N4O2
Formula Weight:
440.73
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GLP-1R antagonist 1 can be used to study the regulatory mechanisms of insulin secretion or play an important role in modeling metabolic diseases.
Library Information
Targets:
Glucagon receptor
Receptors:
GLP-1
Pathways:
GPCR/G protein
Plate Number:
AOCL-4
Plate Location:
d2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
90 mg/mL; 204.2 mM
